(Press-News.org) ROCHESTER, Minn. — Mayo Clinic collaborated with New Phase Ltd. to install the first magnetic nanoparticle-mediated hyperthermia machine for cancer research in the U.S. Hyperthermia is a procedure that uses heat to damage and kill cancer cells. The investigational machine will support research evaluating the safety, feasibility and potential effectiveness of this approach in cancer treatment.
"We have known for more than a century that temperature is the Achilles' heel of cancer, but conventional hyperthermia has limitations and is not widely available," says Scott Lester, M.D., a radiation oncologist at Mayo Clinic. "The hyperthermia technology we've installed is still investigational but may enable us to harness heat in a novel way for advanced cancers, and we're grateful to be the first to use it in our research."
The investigational hyperthermia machine is an electromagnetic induction system that targets the torso. Doctors first administer iron oxide-containing magnetic nanoparticles through an IV, allowing them to collect in tumors. The care team then positions the patient in the machine, where electromagnetic waves heat the tumors to help destroy cancer cells.
"It works like an induction cooktop," Dr. Lester explains. Induction cooktops require special pans to interact with the device. Instead of pans, the tumor absorbs the nanoparticles, effectively turning it into an induction pan. When alternating magnetic fields pulse the pan, it creates heat. A special coating on the nanoparticles limits the temperature to no more than 50 degrees Celsius. The care team also places cooling blankets on patients to keep their body temperature from rising too high and monitors them closely. The hope is that this controlled heating can damage the tumor to slow or stop its growth.
New Phase Ltd. manufactures both the hyperthermia machine and the nanoparticles. Mayo Clinic installed the machine within the Radiation Oncology Department in the Jacobson Building at Mayo Clinic in Rochester. The team completed the installation in November 2025. The first U.S. patient then received hyperthermia as part of a clinical trial in December 2025.
In the clinical trial, researchers are administering the investigational therapy to metastatic solid tumors in any body area except the brain. The investigational therapy can be administered to multiple tumors simultaneously and to cancers that are deep in the body. "We are focusing on patients whose cancers are resistant to multiple lines of systemic therapies and other advanced treatments, including radiotherapy," says Sean Park, M.D., Ph.D., radiation oncologist at Mayo Clinic Comprehensive Cancer Center and co-principal investigator of the trial with Dr. Lester.
"Science has taught us that hyperthermia may be the ultimate sidekick for these treatments," Dr. Lester adds. "We aim for hyperthermia to be the fourth leg of cancer treatment, giving us a different angle to attack cancer and help patients." Researchers also plan to study hyperthermia in combination with other treatments, such as radiation. Combination therapy could allow for lower radiation doses with the same effectiveness or improve outcomes in radiation-resistant tumors.
"The research collaboration between New Phase Ltd. and Mayo Clinic aims to open new treatment possibilities for metastatic cancer patients who currently have limited options," says Ofer Shalev, CEO and co-founder of New Phase Ltd.
Twenty years ago, Mayo Clinic radiation oncologists used ultrasound to heat water-filled bags that were placed on patients' skin, often on the chest wall of women who had recurrent breast cancer after surgery and radiation. "We added the heat to enhance the effects of radiation, and there were times it was very successful," says Nadia Laack, M.D., chair of Radiation Oncology at Mayo Clinic. However, the water bag temperature was unreliable, and patients could experience pain, causing the technique to fall out of favor. Other studies showing the benefits of hyperthermia combined with radiation were also limited by technological constraints.
"Now, we may have a more advanced method to reintroduce hyperthermia into cancer therapy," Dr. Laack says. "If we can demonstrate its effectiveness, we can make hyperthermia more widely available to help patients with complex cancers."
Mayo Clinic has a financial interest in the technology referenced in this news release. Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education and research.
###
About Mayo Clinic
Mayo Clinic is a nonprofit organization committed to innovation in clinical practice, education and research, and providing compassion, expertise and answers to everyone who needs healing. Visit the Mayo Clinic News Network for additional Mayo Clinic news.
About Mayo Clinic Comprehensive Cancer Center
Designated as a comprehensive cancer center by the National Cancer Institute, Mayo Clinic Comprehensive Cancer Center is defining the cancer center of the future, focused on delivering the world's most exceptional patient-centered cancer care for everyone. At Mayo Clinic Comprehensive Cancer Center, a culture of innovation and collaboration is driving research breakthroughs in cancer detection, prevention and treatment to change lives.
About New Phase Ltd.
New Phase Ltd. is a Deep Tech technology company based in Israel. Its mission is to dramatically improve cancer patients' quality of life through innovative and minimally invasive treatments. By leveraging nanotechnology and electromagnetic systems, it aims to provide a precise, groundbreaking solution to one of the world’s biggest health challenges – cancer.
END
Mayo Clinic installs first magnetic nanoparticle hyperthermia system for cancer research in the US
2026-02-17
ELSE PRESS RELEASES FROM THIS DATE:
Calibr-Skaggs and Kainomyx launch collaboration to pioneer novel malaria treatments
2026-02-17
La Jolla, CA and Palo Alto, CA—The Calibr-Skaggs Institute for Innovative Medicines at Scripps Research and Kainomyx, Inc., today announced a new research collaboration to accelerate the discovery and development of next-generation antimalarial drugs. This partnership, supported by the Gates Foundation, brings together Calibr-Skaggs’ world-class drug discovery platform and Kainomyx’s innovative focus on cytoskeletal targets in the Plasmodium species of the parasite that are responsible for the deadliest form of malaria.
Meeting the Unmet Need in Malaria
Malaria remains one of the world’s most devastating infectious diseases, with over 280 million ...
JAX-NYSCF Collaborative and GSK announce collaboration to advance translational models for neurodegenerative disease research
2026-02-17
The Jackson Laboratory–New York Stem Cell Foundation Collaborative (JAX-NYSCF) today announced a five-year strategic research collaboration with GSK focused on advancing human cellular models of neurodegenerative disease, including Alzheimer’s disease.
The collaboration reflects a strategic focus that brings together human stem cell research, advanced data science tools, and large-scale research systems to help close a long-standing gap between scientific discovery and the development of new medicines. The goal is to generate ...
Classifying pediatric brain tumors by liquid biopsy using artificial intelligence
2026-02-17
(MEMPHIS, Tenn. – February 17, 2026) Liquid biopsies, which test body fluids that contain cancerous material, including circulating tumor DNA (ctDNA), are a noninvasive way to learn about a cancer’s biology. However, technological limitations with the small amount of ctDNA available from pediatric brain tumor liquid biopsies have previously stymied broad use of the approach for those patients. To address this, St. Jude Children’s Research Hospital scientists, in collaboration with scientists at the Hopp Children's Cancer Center Heidelberg (KiTZ), German Cancer Research ...
Insilico Medicine initiates AI driven collaboration with leading global cancer center to identify novel targets for gastroesophageal cancers
2026-02-17
Cambridge, MA, February 17, 2025 — Insilico Medicine (“Insilico”, 3696.HK), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, and Memorial Sloan Kettering Cancer Center (MSK) have entered into a collaborative research agreement aimed at discovering new therapeutic targets for gastroesophageal malignancies. The initiative builds on MSK’s global leadership in this field under the direction of Yelena Y. Janjigian, MD, Carroll and Milton Petrie Chair; Chief, GI ...
Immunotherapy plus chemotherapy before surgery shows promise for pancreatic cancer
2026-02-17
A new UCLA investigator-initiated study sponsored by the UCLA Health Jonsson Comprehensive Cancer Center has found that adding immunotherapy to standard chemotherapy before surgery is safe and shows promise for some patients with borderline-resectable pancreatic cancer, a disease that has historically been difficult to treat. The findings, published in Nature Communications, show that while the combination did not produce a clear survival advantage for most patients, a notable subset experienced unusually ...
A “smart fluid” you can reconfigure with temperature
2026-02-17
Imagine a “smart fluid” whose internal structure can be rearranged just by changing temperature.
In a new study in Matter, researchers report a way to overcome a long-standing limitation in a class of “smart fluids” called nematic liquid crystal microcolloids, allowing for reconfigurable self-assembly of micrometer-sized particles dispersed in a nematic liquid crystal host.
The persistent challenge has been that conventional microparticles can induce strong distortions and topological defects in the liquid crystal, which in turn can drive irreversible sticking and clumping, making ...
New research suggests myopia is driven by how we use our eyes indoors
2026-02-17
New York, NY — For years, rising rates of myopia — or nearsightedness — have been widely attributed to increased screen time, especially among children and young adults. But new research from scientists at the SUNY College of Optometry suggests the story may be more complicated — and more human. In a new study to be published in Cell Reports, researchers propose that myopia may be driven less by screens themselves and more by a common indoor visual habit: prolonged close-up focus in low-light environments, which limits how much light reaches ...
Scientists develop first-of-its-kind antibody to block Epstein Barr virus
2026-02-17
SEATTLE – February 17, 2026 – Fred Hutch Cancer Center scientists reached a crucial milestone in blocking Epstein Barr virus (EBV), a pathogen estimated to infect 95% of the global population that is linked to multiple types of cancer, neurodegenerative diseases and other chronic health conditions.
Using mice with human antibody genes, the research team developed new genetically human monoclonal antibodies that prevent two key antigens on the surface of the virus from binding to and entering human immune cells. Published in Cell Reports Medicine, the ...
With the right prompts, AI chatbots analyze big data accurately
2026-02-17
In an early test of how AI can be used to decipher large amounts of health data, researchers at UC San Francisco and Wayne State University found that generative AI tools could perform orders of magnitude faster — and in some cases better than computer science teams that had spent months poring over the data.
Teams of scientists and scientists paired with AI were given the same task: predict preterm birth based on data from more than 1,000 pregnant women.
Even a junior research duo composed of a master’s student at UCSF, Reuben Sarwal, and a high school ...
Leisure-time physical activity and cancer mortality among cancer survivors
2026-02-17
About The Study: In this analysis of 6 pooled cohorts, higher levels of moderate to vigorous physical activity (MVPA) after a cancer diagnosis were associated with lower risk of cancer mortality among people previously diagnosed with 1 of 7 cancers not commonly studied for their association with MVPA. These findings suggest that it is important for health care professionals to promote physical activity for longevity and overall health among people living with and beyond cancer.
Corresponding Author: To contact the corresponding author, Erika Rees-Punia, PhD, email erika.rees-punia@cancer.org.
To ...